Could an arthritis drug tame a tough transplant complication?

NCT ID NCT01954979

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug abatacept in people with chronic graft-versus-host disease (cGVHD) that is not controlled by steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial has two phases: first, to find a safe dose of abatacept, and second, to see if it helps control the disease. Fifty-six participants will receive abatacept and be monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abatacept
What this could lead to
If it works, this could offer a new treatment option for people with chronic graft-versus-host disease that does not respond to standard steroids.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to everyone. Abatacept can cause serious immune suppression and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.